Targets › TOP1
33 programs from 27 companies in 350 trials: 172 Phase 2, 91 Phase 1, 85 Phase 3, 2 Phase 4; Oncology, Other, Gastroenterology; next expected readout Nov 2026.
Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme…. (UniProt, P11387)
Open in Phaseline: the race on TOP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Datopotamab Deruxtecan Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 4 | Stomatitis; Breast Cancer; Metastatic Non-small Cell Lung Cancer; Non-small Cell Lung Cancer … | Dec 2026 |
| AstraZeneca | Trastuzumab deruxtecan Receptor protein-tyrosine kinase erbB-2 binding agent; DNA topoisomerase I inhibitor | ERBB2, TOP1 | Phase 4 | BREAST CANCER; Advanced or Metastatic Breast Cancer; Breast Neoplasms; Breast Cancer; HER2-positive; Metastatic … | Dec 2026 |
| Sichuan Kelun-Biotech Biopharmaceutical | Sacituzumab Govitecan (SKB264) Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 3 | Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer … | Nov 2026 |
| Gilead Sciences | Sacituzumab Govitecan Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 3 | Metastatic Breast Cancer; Non-Small Cell Lung Cancer; Triple Negative Breast Cancer; Locally Advanced or Unresectable Metastatic Breast Cancer … | Dec 2026 |
| Daiichi Sankyo | Datopotamab Deruxtecan Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 3 | Non-small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer; Urothelial Cancer; Advanced or Metastatic NSCLC … | Dec 2026 |
| Daiichi Sankyo | Patritumab Deruxtecan Receptor tyrosine-protein kinase erbB-3 binding agent; DNA topoisomerase I inhibitor | ERBB3, TOP1 | Phase 3 | Nonsquamous Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer Metastatic; Advanced Solid Tumor; Non-Small Cell Lung Cancer (NSCLC) … | Dec 2026 |
| Merck & Co. (MSD) | Sacituzumab Govitecan Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 3 | Carcinoma, Non-Small-Cell Lung; Gastroesophageal Cancer; Non-small Cell Lung Cancer (NSCLC); Breast Neoplasms … | Jan 2027 |
| Daiichi Sankyo | Trastuzumab Deruxtecan Receptor protein-tyrosine kinase erbB-2 binding agent; DNA topoisomerase I inhibitor | ERBB2, TOP1 | Phase 3 | Breast Cancer; Gastric Cancer, Adenocarcinoma; Advanced Cancer; Gastric Cancer … | Mar 2027 |
| Merck & Co. (MSD) | Patritumab Deruxtecan Receptor tyrosine-protein kinase erbB-3 binding agent; DNA topoisomerase I inhibitor | ERBB3, TOP1 | Phase 3 | Breast Neoplasms; Non-small Cell Lung Cancer; Gastroesophageal Junction; Gastrointestinal Cancer … | May 2028 |
| Luye Pharma Group | LY01610 Topoisomerase I inhibitor (liposomal formulation) | TOP1 | Phase 3 | Relapsed Small Cell Lung Cancer | Jun 2028 |
| Alliance for Clinical Trials in Oncology | Irinotecan Hydrochloride DNA topoisomerase I inhibitor | TOP1 | Phase 3 | Pancreatic Adenosquamous Carcinoma | Dec 2028 |
| National Cancer Institute (NCI) | pH Low Insertion Peptide-exatecan Conjugate CBX-12 TOP1 inhibitor conjugate | TOP1 | Phase 2 | Metastatic Mismatch Repair Proficient Colorectal Carcinoma; Advanced Malignant Solid Neoplasm | Dec 2026 |
| Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | Topotecan DNA topoisomerase I inhibitor | TOP1 | Phase 2 | SCLC | Dec 2026 |
| Klus Pharma | Sacituzumab Govitecan (SKB264) Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 2 | Non-small Cell Lung Cancer; Solid Tumor; Epithelial Ovarian Cancer | Dec 2026 |
| OHSU Knight Cancer Institute | Irinotecan Hydrochloride DNA topoisomerase I inhibitor | TOP1 | Phase 2 | Pancreatic Adenocarcinoma | Jan 2027 |
| Taichung Veterans General Hospital | NALIRIFOX Liposomal irinotecan (topoisomerase I inhibitor) in combination with fluorouracil (thymidy | TOP1, TYMS | Phase 2 | Resectable Pancreatic Adenocarcinoma | Feb 2027 |
| National Cancer Institute (NCI) | Topotecan Hydrochloride DNA topoisomerase I inhibitor | TOP1 | Phase 2 | Extensive Stage Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm | Mar 2027 |
| UNC Lineberger Comprehensive Cancer Center | Irinotecan Hydrochloride DNA topoisomerase I inhibitor | TOP1 | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | Jul 2027 |
| Memorial Sloan Kettering Cancer Center | irinotecan hydrochloride DNA topoisomerase I inhibitor | TOP1 | Phase 2 | Sarcoma | Oct 2027 |
| Sun Yat-sen University | NALIRIFOX Combination chemotherapy regimen containing liposomal irinotecan (TOP1 inhibitor), oxalipl | TOP1, TOPO1 | Phase 2 | Rectal Cancers | Jun 2028 |
| Shandong Cancer Hospital and Institute | NALIRIFOX Combination chemotherapy with liposomal irinotecan (topoisomerase I inhibitor), oxaliplati | TOP1, ERCC1 | Phase 2 | Pancreatic Cancer | Oct 2028 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | NALIRIFOX Liposomal irinotecan (SN-38 topoisomerase I inhibitor) combined with fluorouracil and oxal | TOP1 | Phase 2 | NENS | Dec 2028 |
| Children's Oncology Group | Irinotecan Hydrochloride DNA topoisomerase I inhibitor | TOP1 | Phase 2 | High Risk Neuroblastoma | Mar 2029 |
| CEBIOTEX | 7-Ethyl-10-Hydroxycamptothecin (CEB-01) DNA topoisomerase I inhibitor | TOP1 | Phase 2 | Locally Resectable Pediatrics Tumors | May 2029 |
| Targeted Therapy Technologies | Topotecan DNA topoisomerase I inhibitor | TOP1 | Phase 2 | Retinoblastoma | Nov 2029 |
| M.D. Anderson Cancer Center | Puxitatug Samrotecan (AZD8205) Topoisomerase I inhibitor | TOP1 | Phase 2 | Adenoid Cystic Carcinoma | Dec 2029 |
| Mayo Clinic | Pegylated SN-38 Conjugate PLX038 Pegylated SN-38 conjugate; topoisomerase I inhibitor | TOP1 | Phase 2 | Platinum-Resistant Fallopian Tube Carcinoma | Feb 2030 |
| Fujifilm Pharmaceuticals U.S.A. | Topotecan (FF-10850) DNA topoisomerase I inhibitor | TOP1 | Phase 1 | Advanced Solid Tumors; Retinoblastoma; Pleuropulmonary Blastoma; Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment … | Dec 2026 |
| St. Jude Children's Research Hospital | Irinotecan Hydrochloride DNA topoisomerase I inhibitor | TOP1 | Phase 1 | Recurrent Solid Tumor | Dec 2026 |
| National Cancer Institute (NCI) | Irinotecan Hydrochloride DNA topoisomerase I inhibitor | TOP1 | Phase 1 | Metastatic Colorectal Carcinoma; Adult Solid Neoplasm | Mar 2027 |
| National Health Research Institutes, Taiwan | Irinotecan Hydrochloride DNA topoisomerase I inhibitor | TOP1 | Phase 1 | Metastatic Gastric Adenocarcinoma | Dec 2027 |
| National Institute of Neurological Disorders and Stroke (NINDS) | LMP744 Indenoisoquinolone C-MYC/TOPOISOMERASE 1 inhibitor | MYC, TOP1 | Phase 1 | Recurrent Glioblastoma | Dec 2030 |
| City of Hope Medical Center | Irinotecan Hydrochloride DNA topoisomerase I inhibitor | TOP1 | Phase 1 | Recurrent Anaplastic Astrocytoma | – |
Breast Cancer (40) Metastatic Breast Cancer (12) Non-small Cell Lung Cancer (12) Non-Small Cell Lung Cancer (8) Triple Negative Breast Cancer (8) Breast Neoplasms (6) Endometrial Cancer (6) Gastric Cancer (6) HER2-positive Breast Cancer (6) Metastatic Breast Cancer ( HER2 Negative) (5) Advanced Solid Tumor (5) Ovarian Cancer (4)
small molecule (16), mixed (11), antibody (3), protein or peptide (1)
Daiichi Sankyo (3) National Cancer Institute (NCI) (3) AstraZeneca (2) Merck & Co. (MSD) (2) Gilead Sciences (1) St. Jude Children's Research Hospital (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) National Institute of Neurological Disorders and Stroke (NINDS) (1) Klus Pharma (1) Memorial Sloan Kettering Cancer Center (1) National Health Research Institutes, Taiwan (1) Sun Yat-sen University (1) Alliance for Clinical Trials in Oncology (1) Mayo Clinic (1) Fujifilm Pharmaceuticals U.S.A. (1) Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair (1) Targeted Therapy Technologies (1) City of Hope Medical Center (1) UNC Lineberger Comprehensive Cancer Center (1) Shandong Cancer Hospital and Institute (1)
TACSTD2 (6) ERBB2 (2) ERBB3 (2) MYC (1) TOPO1 (1) ERCC1 (1) TYMS (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.